0.10 (-30.32%)
As of Oct 13, 2023
Source:
Bellerophon Therapeutics, Inc. is a clinical-stage therapeutics company focused on developing innovative products that address significant unmet medical needs in the treatment of cardiopulmonary diseases. Our focus is the continued development of our nitric oxide therapy for patients with or at risk of pulmonary hypertension, or PH, using our proprietary pulsatile nitric oxide delivery platform, INOpulse.
Country | United States |
Headquarters | warren, new jersey |
Phone Number | 908-574-4770 |
Industry | manufacturing |
CEO | Peter Fernandes |
Website | www.bellerophon.com |